AxoGen, Inc. (AXGN) Shares Bought by Menta Capital LLC
Menta Capital LLC grew its holdings in AxoGen, Inc. (NASDAQ:AXGN) by 7.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 116,845 shares of the medical equipment provider’s stock after purchasing an additional 7,777 shares during the quarter. Menta Capital LLC owned about 0.35% of AxoGen worth $1,957,000 as of its most recent filing with the SEC.
Several other large investors have also modified their holdings of AXGN. Teachers Advisors LLC raised its stake in shares of AxoGen by 25.5% in the fourth quarter. Teachers Advisors LLC now owns 48,740 shares of the medical equipment provider’s stock valued at $439,000 after acquiring an additional 9,893 shares during the last quarter. Bank of Montreal Can raised its position in AxoGen by 978.5% in the 1st quarter. Bank of Montreal Can now owns 14,981 shares of the medical equipment provider’s stock worth $157,000 after purchasing an additional 13,592 shares during the last quarter. TFS Capital LLC bought a new position in AxoGen in the 1st quarter worth approximately $120,000. Parametric Portfolio Associates LLC raised its position in AxoGen by 0.9% in the 1st quarter. Parametric Portfolio Associates LLC now owns 10,843 shares of the medical equipment provider’s stock worth $113,000 after purchasing an additional 93 shares during the last quarter. Finally, Trexquant Investment LP bought a new position in AxoGen in the 1st quarter worth approximately $183,000. 66.77% of the stock is currently owned by institutional investors.
AxoGen, Inc. (NASDAQ:AXGN) opened at 18.65 on Friday. The company’s market cap is $619.93 million. The company has a 50-day moving average of $16.58 and a 200 day moving average of $14.19. AxoGen, Inc. has a 52-week low of $7.65 and a 52-week high of $19.20.
AxoGen (NASDAQ:AXGN) last issued its earnings results on Wednesday, August 2nd. The medical equipment provider reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. AxoGen had a negative net margin of 27.50% and a negative return on equity of 114.64%. The firm had revenue of $15.20 million for the quarter, compared to analyst estimates of $14.40 million. During the same quarter last year, the business posted ($0.09) earnings per share. The company’s quarterly revenue was up 46.2% on a year-over-year basis. Equities research analysts predict that AxoGen, Inc. will post ($0.31) EPS for the current year.
TRADEMARK VIOLATION WARNING: “AxoGen, Inc. (AXGN) Shares Bought by Menta Capital LLC” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/axogen-inc-axgn-shares-bought-by-menta-capital-llc/1579978.html.
Several research analysts recently weighed in on AXGN shares. Roth Capital restated a “buy” rating and issued a $21.00 price objective (up previously from $18.00) on shares of AxoGen in a research report on Tuesday, September 12th. Cantor Fitzgerald restated a “buy” rating and issued a $18.00 price objective on shares of AxoGen in a research report on Monday, August 21st. BidaskClub cut shares of AxoGen from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. ValuEngine upgraded shares of AxoGen from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Leerink Swann started coverage on shares of AxoGen in a research report on Monday, July 31st. They issued an “outperform” rating and a $22.00 price objective for the company. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. AxoGen presently has an average rating of “Buy” and an average price target of $17.20.
In other AxoGen news, Director Robert James Rudelius sold 16,143 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $18.00, for a total value of $290,574.00. Following the sale, the director now owns 43,273 shares in the company, valued at $778,914. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 9.33% of the company’s stock.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Want to see what other hedge funds are holding AXGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AxoGen, Inc. (NASDAQ:AXGN).
Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.